Efficacy of gene-therapy based on adenovirus encoding granulocyte-macrophage colony-stimulating factor in drug-sensitive and drug-resistant experimental pulmonary tuberculosis
- 1 September 2016
- journal article
- research article
- Published by Elsevier in Tuberculosis
- Vol. 100, 5-14
Abstract
No abstract availableKeywords
Funding Information
- Mexican National Council for Science and Technology (Fon.Inst./58/2016)
- CONACyT (Fon.Inst./58/2016, 253053)
This publication has 34 references indexed in Scilit:
- Immunotherapeutic effects of recombinant adenovirus encoding granulocyte–macrophage colony-stimulating factor in experimental pulmonary tuberculosisClinical and Experimental Immunology, 2013
- Adjunct Immunotherapies for TuberculosisThe Journal of Infectious Diseases, 2012
- In vitro differentiation of human macrophages with enhanced antimycobacterial activityJournal of Clinical Investigation, 2011
- Delivery of Therapeutic ProteinsJournal of Pharmaceutical Sciences, 2010
- Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agentsVirology, 2009
- Simple dihydrosphyngosine analogues with potent activity against MDR-Mycobacterium tuberculosisBioorganic & Medicinal Chemistry Letters, 2009
- Immunomodulation with Recombinant Interferon-γ1b in Pulmonary TuberculosisPLOS ONE, 2009
- Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces theAspergillusBurden in an Immunosuppressed Murine Model of Pulmonary AspergillosisAntimicrobial Agents and Chemotherapy, 2008
- Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative ResearchPLOS Medicine, 2007
- An Outbreak of Multidrug-Resistant Tuberculosis among Hospitalized Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1992